Federal employment and medical cannabis: what the April 2026 Schedule III order did not change

The April 22, 2026 DOJ rescheduling order produced an entirely understandable wave of confusion among federal employees, military service members, security-clearance holders, and DOT-regulated transportation workers. The headline read like a federal acceptance of medical cannabis. The fine print did not deliver that.

Schedule III status changed the federal tax treatment of state-licensed medical cannabis operators and lowered the procedural barrier for FDA-funded cannabis research. It did not change the rules under which federal employment, security clearance, military service, and DOT-regulated work are governed. Those frameworks (UCMJ Article 112a, Security Executive Agent Directive 4, the Drug-Free Workplace Act, 49 CFR Part 40) operate on parallel legal authorities that the April 22 order did not touch.

This article walks through each framework as of May 2026, explains what state medical-cannabis status does and does not protect against, and identifies the small number of edge cases where the rules are evolving.

Active-duty military: UCMJ Article 112a

The most absolute prohibition. Article 112a of the Uniform Code of Military Justice (10 U.S.C. § 912a) makes it a court-martial offense for any active-duty service member to wrongfully use, possess, manufacture, distribute, import, export, or introduce a Schedule I, II, or III controlled substance — including, post-April 2026, the rescheduled Schedule III categories of FDA-approved and state-medical marijuana.

The maximum punishment for simple wrongful use of marijuana under Article 112a:

• Dishonorable discharge.
• Forfeiture of all pay and allowances.
• Confinement up to two years (with additional time for aggravating circumstances — Schedule I-III substances generally carry up to five years for distribution; aggravating contexts like on-duty use, while operating military equipment, or while receiving certain hazardous-duty pay can add five years).

Article 112a applies regardless of:

• Whether the service member is in a state where cannabis is legal.
• Whether the service member holds a state medical-cannabis card.
• Whether the use occurred off-duty and off-base.
• Whether the substance is Schedule III rather than Schedule I.

The Department of Defense issued a separate February 2020 policy explicitly prohibiting service members from consuming hemp or CBD products, regardless of stated THC content. This policy has not been rescinded; it remains the operative DoD position.

For active-duty service members: medical cannabis is not an option. The fact that you can purchase legally in your state of residence does not change your UCMJ exposure. Discharge for cannabis use is among the most common adverse separations for enlisted personnel.

For veterans (separated from service): UCMJ jurisdiction ends with separation. Veterans are subject to their state's medical-cannabis rules and may participate in state programs. The VA has a separate framework: VA practitioners cannot recommend or certify medical cannabis under federal Schedule I authority, but VA primary care does not deny treatment to veterans for state-legal medical cannabis use.

Security clearance: SEAD 4 and Adjudicative Guideline H

The federal security-clearance framework operates under Security Executive Agent Directive 4 (SEAD 4), which establishes the Adjudicative Guidelines that clearance-granting agencies use to evaluate applicants and current clearance holders. The relevant guideline is Guideline H: Drug Involvement and Substance Misuse.

The April 22, 2026 DOJ order did not modify SEAD 4 or Guideline H. The Office of the Director of National Intelligence (ODNI) issued separate guidance in 2021 reiterating that:

• Marijuana use is a security-clearance concern under Guideline H.
• State legalization does not change federal-employee adjudication standards.
• Past marijuana use is mitigable but current use is generally disqualifying.

The rescheduling produced an immediate round of clarification from ODNI, federal-employment legal practitioners, and clearance-adjudication writers: Schedule III status does not eliminate marijuana as an adjudicative concern. The relevant categories under SEAD 4 / Guideline H remain:

• Current use of any controlled substance (Schedule I, II, or III) without proper authorization is disqualifying.
• Past use is mitigated by passage of time, demonstration of intent to abstain, and absence of dependency.
• Use while holding a clearance is a particularly serious adverse factor that typically results in clearance revocation.

Additional clearance-relevant guidelines that may apply:

• Guideline E: Personal Conduct — pertinent if marijuana use was concealed during a background investigation.
• Guideline J: Criminal Conduct — pertinent if marijuana use resulted in any prosecution (including state-level prosecutions).

For a clearance holder considering state-legal medical cannabis use:

• Initiating use will likely be reportable to the agency's security office and is generally treated as disqualifying.
• "I have a state medical card" is not a recognized mitigating factor under Guideline H. The clearance framework treats federal authority as controlling.
• The only FDA-approved marijuana product (Epidiolex) is allowed for clearance holders prescribed it for an approved indication, because it is treated as a prescription drug.
• Other state-medical-cannabis products remain disqualifying.

This is the framework where the gap between state-level legality and federal-level eligibility produces the most painful patient choices. Veterans with PTSD or TBI who hold clearances must choose between medical cannabis (effective for many) and clearance retention.

Federal civilian employees: Drug-Free Workplace Act and OPM guidance

Federal civilian employees (GS-series, SES, federal contractors working on federal sites) operate under the Drug-Free Workplace Act of 1988 and Office of Personnel Management (OPM) guidance. The framework:

• Federal agencies must maintain a drug-free workplace policy.
• "Illegal drug use" is defined by reference to the Controlled Substances Act.
• Schedule I-V substances are covered.

The April 22, 2026 order's narrow Schedule III move does not alter federal-employee drug-testing obligations. Federal agencies continue to:

• Test for marijuana use as part of pre-employment and random testing programs for safety-sensitive and security-sensitive positions.
• Treat positive results as the basis for adverse personnel action.
• Apply these rules regardless of state medical-cannabis status.

A federal employee who tests positive for THC metabolites faces the same consequences whether the substance was consumed through:

• Adult-use purchase in a recreational-legal state.
• State-licensed medical purchase under a state medical-cannabis card.
• Hemp-derived product (which can produce positive THC tests at sufficient consumption levels).

OPM has not issued new guidance post-rescheduling. Practitioners reviewing the implications have uniformly concluded that pre-existing rules continue to govern federal employment.

DOT-regulated transportation: 49 CFR Part 40

For workers in safety-sensitive transportation roles — commercial driver's license holders, airline pilots, railroad engineers, transit operators, maritime workers — the Department of Transportation's drug-testing regulations at 49 CFR Part 40 apply.

Part 40 specifies:

• Five-panel urine testing (marijuana, cocaine, opiates, amphetamines, PCP).
• Marijuana is on the test panel.
• A positive test is disqualifying from safety-sensitive duties.
• Medical-cannabis use is not a defense.

The DOT's Office of Drug and Alcohol Policy and Compliance (ODAPC) has maintained, since the original 1991 promulgation of Part 40 and through every subsequent state legalization wave, that:

• State medical-cannabis programs do not exempt DOT-regulated workers from federal testing rules.
• A state medical-cannabis card does not constitute a "valid medical explanation" for a positive drug test.
• The Medical Review Officer (MRO) reviewing a positive result is instructed to verify the result regardless of state-program participation.

ODAPC issued a specific "Medical Marijuana Notice" reiterating these points. The notice has not been withdrawn post-rescheduling. CDL holders, transit operators, and other DOT-regulated workers remain subject to the same rules they were subject to on April 21, 2026.

The DOT's pre-employment, random, post-accident, return-to-duty, and follow-up testing programs all continue to test for marijuana. A positive result triggers immediate removal from safety-sensitive duty pending evaluation by a substance-abuse professional.

Federal civilian contractors

Federal contractors (private-sector employees of companies holding federal contracts subject to the Drug-Free Workplace Act, Department of Defense contractor rules, or specific contract-clause requirements) generally operate under:

• The Drug-Free Workplace Act (for contracts above certain dollar thresholds).
• Department of Defense Federal Acquisition Regulation Supplement (DFARS) drug-testing requirements for defense contracts.
• Contract-specific drug-testing clauses.

The pattern matches federal civilian employees: marijuana use is treated as illegal-drug use; positive tests are grounds for adverse action; state-medical-cannabis status is not a recognized defense.

For contractors holding security clearances, the SEAD 4 framework also applies in parallel.

The narrow exception: FDA-approved Epidiolex

There is one cannabis-derived prescription drug that does not produce the disqualifying outcomes described above: Epidiolex (cannabidiol oral solution), approved by FDA for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.

Because Epidiolex is FDA-approved for specific indications and pre-April 2026 was Schedule V (now also subject to the rescheduling), federal employment and security-clearance frameworks treat its use as legitimate prescription drug use when:

• The patient has an FDA-labeled indication.
• The drug is prescribed by a licensed practitioner with DEA registration.
• The patient documents the prescription through normal employment-medical or clearance-adjudication channels.

This is the narrow circle in which "I take a cannabis-derived medication" does not produce the federal-employment cascade described elsewhere in this article. The circle is small: roughly the population of patients with refractory pediatric epilepsy syndromes for whom Epidiolex is the approved therapy.

What the April 22 order would have to do to change federal employment rules

For the federal-employment frameworks to align with state medical-cannabis programs, several distinct actions would be required:

• Congressional legislation modifying the Drug-Free Workplace Act or creating an explicit medical-cannabis exemption for state-program participants.
• DOT regulatory action modifying Part 40 to remove marijuana from the test panel for DOT-regulated workers, or to recognize state medical-cannabis status as a valid medical explanation.
• Executive Branch action modifying SEAD 4 / Adjudicative Guideline H to recognize state medical-cannabis use as not disqualifying.
• DoD policy change modifying the UCMJ Article 112a enforcement posture or establishing a medical-cannabis exception (which would require statutory amendment, not just policy change).

None of these has occurred. None is scheduled to occur in the near term. The April 22 rescheduling order does not produce any of them automatically.

Practical posture for state-legal medical patients in federal-adjacent roles

Five practical points:

1. If you are active-duty military, medical cannabis is not an option. UCMJ Article 112a applies. Separation for cannabis use is a real and documented consequence.
2. If you hold a security clearance, initiating medical cannabis use will likely result in clearance loss. Established cannabis use should be discussed with a security-clearance attorney before applying for a clearance.
3. If you are a federal civilian employee, the Drug-Free Workplace Act applies. Pre-employment testing and random testing programs are in place for many positions. Medical-cannabis status is not a defense.
4. If you hold a CDL or work in a DOT-regulated transportation role, 49 CFR Part 40 applies. Medical-cannabis status is not a defense. A positive test removes you from safety-sensitive duty.
5. If you are a veteran without current federal employment or clearance, you may participate in state medical-cannabis programs. The VA will provide normal medical care; the VA cannot certify or recommend medical cannabis under federal Schedule I authority but does not deny treatment for state-legal use.

For federal-adjacent workers, the most accurate posture in May 2026 is: state medical-cannabis programs and federal employment rules operate on parallel tracks that do not intersect favorably for the patient. The April 2026 rescheduling was meaningful for state-licensed operators and for cannabis research. It was not meaningful for federal employment or military service. Patients in those roles should plan accordingly.

[Last reviewed 2026-05-18. This is informational only — not medical or legal advice. Federal-employment and security-clearance questions should be reviewed with qualified counsel familiar with the specific framework applicable to your role.]